|
1
|
Dimitriou F, Krattinger R, Ramelyte E,
Barysch MJ, Micaletto S, Dummer R and Goldinger SM: The World of
melanoma: Epidemiologic, genetic, and anatomic differences of
melanoma across the globe. Curr Oncol Rep. 20:872018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cantor JR and Sabatini DM: Cancer cell
metabolism: One hallmark, many faces. Cancer Discov. 2:881–898.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Courtnay R, Ngo DC, Malik N, Ververis K,
Tortorella SM and Karagiannis TC: Cancer metabolism and the Warburg
effect: The role of HIF-1 and PI3K. Mol Biol Rep. 42:841–851. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dong Z and Cui H: Epigenetic modulation of
metabolism in glioblastoma. Semin Cancer Biol. 57:45–51. 2019.
View Article : Google Scholar
|
|
8
|
Zhu S, Dong Z, Ke X, Hou J, Zhao E, Zhang
K, Wang F, Yang L, Xiang Z and Cui H: The roles of sirtuins family
in cell metabolism during tumor development. Semin Cancer Biol.
57:59–71. 2019. View Article : Google Scholar
|
|
9
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paik JH, Kollipara R, Chu G, Ji H, Xiao Y,
Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, et al: FoxOs are
lineage-restricted redundant tumor suppressors and regulate
endothelial cell homeostasis. Cell. 128:309–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yadav RK, Chauhan AS, Zhuang L and Gan B:
FoxO transcription factors in cancer metabolism. Semin Cancer Biol.
50:65–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hornsveld M, Dansen TB, Derksen PW and
Burgering BMT: Re-evaluating the role of FOXOs in cancer. Semin
Cancer Biol. 50:90–100. 2018. View Article : Google Scholar
|
|
13
|
Ma Z, Xin Z, Hu W, Jiang S, Yang Z, Yan X,
Li X, Yang Y and Chen F: Forkhead box O proteins: Crucial
regulators of cancer EMT. Semin Cancer Biol. 50:21–31. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong Z, Zhong X, Lei Q, Chen F and Cui H:
Transcriptional activation of SIRT6 via FKHRL1/FOXO3a inhibits the
Warburg effect in glioblastoma cells. Cell Signal. 60:100–113.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shukla S, Shukla M, Maclennan GT, Fu P and
Gupta S: Deregulation of FOXO3A during prostate cancer progression.
Int J Oncol. 34:1613–1620. 2009.PubMed/NCBI
|
|
16
|
Herzog CR, Blake DC Jr, Mikse OR,
Grigoryeva LS and Gundermann EL: FoxO3a gene is a target of
deletion in mouse lung adenocarcinoma. Oncol Rep. 22:837–843. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang L, Cao XC, Cao JG, Liu F, Quan MF,
Sheng XF and Ren KQ: Casticin induces ovarian cancer cell apoptosis
by repressing FoxM1 through the activation of FOXO3a. Oncol Lett.
5:1605–1610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Y, Peng K, Li H, Zhuang R, Wang Y, Li
W, Yu S, Liang L, Xu X and Liu T: SP1 upregulated FoxO3a promotes
tumor progression in colorectal cancer. Oncol Rep. 39:2235–2242.
2018.PubMed/NCBI
|
|
19
|
Ikeda JI, Wada N, Nojima S, Tahara S,
Tsuruta Y, Oya K and Morii E: ID1 upregulation and FoxO3a
downregulation by epsteinbarr virus-encoded LMP1 in Hodgkin's
lymphoma. Mol Clin Oncol. 5:562–566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferber EC, Peck B, Delpuech O, Bell GP,
East P and Schulze A: FOXO3a regulates reactive oxygen metabolism
by inhibiting mitochondrial gene expression. Cell Death Differ.
19:968–979. 2012. View Article : Google Scholar :
|
|
21
|
Yu T, Ji J and Guo YL: MST1 activation by
curcumin mediates JNK activation, Foxo3a nuclear translocation and
apoptosis in melanoma cells. Biochem Biophys Res Commun. 441:53–58.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Egger ME, McNally LR, Nitz J, McMasters KM
and Gomez-Gutierrez JG: Adenovirus-mediated FKHRL1/TM sensitizes
melanoma cells to apoptosis induced by temozolomide. Hum Gene Ther
Clin Dev. 25:186–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hilmi C, Larribere L, Deckert M, Rocchi S,
Giuliano S, Bille K, Ortonne JP, Ballotti R and Bertolotto C:
Involvement of FKHRL1 in melanoma cell survival and death. Pigment
Cell Melanoma Res. 21:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan F, Liao R, Farhan M, Wang T, Chen J,
Wang Z, Little PJ and Zheng W: Elucidating the role of the FoxO3a
transcription factor in the IGF-1-induced migration and invasion of
uveal melanoma cancer cells. Biomed Pharmacother. 84:1538–1550.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Wang M, Liu Y, Zou J, Yang R, Xuan F, Wang
Y, Gao N and Cui H: Transcriptional co-activator TAZ sustains
proliferation and tumorigenicity of neuroblastoma by targeting CTGF
and PDGF-β. Oncotarget. 6:9517–9530. 2015.PubMed/NCBI
|
|
27
|
Yang R, Yi L, Dong Z, Ouyang Q, Zhou J,
Pang Y, Wu Y, Xu L and Cui H: Tigecycline inhibits glioma growth by
regulating miRNA-199b-5p-HES1-AKT pathway. Mol Cancer Ther.
15:421–429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He J, Zhao Y, Zhao E, Wang X, Dong Z, Chen
Y, Yang L and Cui H: Cancer-testis specific gene OIP5: A downstream
gene of E2F1 that promotes tumorigenesis and metastasis in
glioblastoma by stabilizing E2F1 signalling. Neuro Oncol.
20:1173–1184. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johnson DB and Puzanov I: Treatment of
NRAS-mutant melanoma. Curr Treat Options Oncol. 16:152015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Willcox BJ, Donlon TA, He Q, Chen R, Grove
JS, Yano K, Masaki KH, Willcox DC, Rodriguez B and Curb JD: FOXO3A
genotype is strongly associated with human longevity. Proc Natl
Acad Sci USA. 105:13987–13992. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirvonen K, Laivuori H, Lahti J,
Strandberg T, Eriksson JG and Hackman P: SIRT6 polymorphism
rs117385980 is associated with longevity and healthy aging in
Finnish men. BMC Med Genet. 18:412017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tao R, Xiong X, DePinho RA, Deng CX and
Dong XC: FoxO3 transcription factor and Sirt6 deacetylase regulate
low density lipoprotein (LDL)-cholesterol homeostasis via control
of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene
expression. J Biol Chem. 288:29252–29259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tao R, Xiong X, DePinho RA, Deng CX and
Dong XC: Hepatic SREBP-2 and cholesterol biosynthesis are regulated
by FoxO3 and Sirt6. J Lipid Res. 54:2745–2753. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim HS, Xiao C, Wang RH, Lahusen T, Xu X,
Vassilopoulos A, Vazquez-Ortiz G, Jeong WI, Park O, Ki SH, et al:
Hepatic-specific disruption of SIRT6 in mice results in fatty liver
formation due to enhanced glycolysis and triglyceride synthesis.
Cell Metab. 12:224–236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong L, D'Urso A, Toiber D, Sebastian C,
Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD,
Nir T, et al: The histone deacetylase Sirt6 regulates glucose
homeostasis via Hif1alpha. Cell. 140:280–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan F, Liao R, Lin S, Deng X, Little PJ
and Zheng W: Forkhead box protein O3 suppresses uveal melanoma
development by increasing the expression of Bcl2like protein 11 and
cyclindependent kinase inhibitor 1B. Mol Med Rep. 17:3109–3114.
2018.
|
|
37
|
Scott DA, Richardson AD, Filipp FV,
Knutzen CA, Chiang GG, Ronai ZA, Osterman AL and Smith JW:
Comparative metabolic flux profiling of melanoma cell lines: Beyond
the Warburg effect. J Biol Chem. 286:42626–42634. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hall A, Meyle KD, Lange MK, Klima M,
Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen
PB, et al: Dysfunctional oxidative phosphorylation makes malignant
melanoma cells addicted to glycolysis driven by the (V600E)BRAF
oncogene. Oncotarget. 4:584–599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Falkenius J, Lundeberg J, Johansson H,
Tuominen R, Frostvik-Stolt M, Hansson J and Egyhazi Brage S: High
expression of glycolytic and pigment proteins is associated with
worse clinical outcome in stage III melanoma. Melanoma Res.
23:452–460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Najera L, Alonso-Juarranz M, Garrido M,
Ballestín C, Moya L, Martínez-Díaz M, Carrillo R, Juarranz A, Rojo
F, Cuezva JM and Rodríguez-Peralto JL: Prognostic implications of
markers of the metabolic phenotype in human cutaneous melanoma. Br
J Dermatol. 181:114–127. 2019. View Article : Google Scholar
|
|
41
|
Koch A, Lang SA, Wild PJ, Gantner S, Mahli
A, Spanier G, Berneburg M, Müller M, Bosserhoff AK and Hellerbrand
C: Glucose transporter isoform 1 expression enhances metastasis of
malignant melanoma cells. Oncotarget. 6:32748–32760. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ho J, de Moura MB, Lin Y, Vincent G,
Thorne S, Duncan LM, Hui-Min L, Kirkwood JM, Becker D, Van Houten B
and Moschos SJ: Importance of glycolysis and oxidative
phosphory-lation in advanced melanoma. Mol Cancer. 11:762012.
View Article : Google Scholar
|
|
43
|
Sebastián C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kleszcz R, Paluszczak J, Krajka-Kuźniak V
and Baer-Dubowska W: The inhibition of c-MYC transcription factor
modulates the expression of glycolytic and glutaminolytic enzymes
in FaDu hypo-pharyngeal carcinoma cells. Adv Clin Exp Med.
27:735–742. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Choe M, Brusgard JL, Chumsri S, Bhandary
L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD,
et al: The RUNX2 transcription factor negatively regulates SIRT6
expression to alter glucose metabolism in breast cancer cells. J
Cell Biochem. 116:2210–2226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu M, Dickinson SI, Wang X and Zhang J:
Expression and function of SIRT6 in muscle invasive urothelial
carcinoma of the bladder. Int J Clin Exp Pathol. 7:6504–6513.
2014.PubMed/NCBI
|
|
47
|
Feng XX, Luo J, Liu M, Yan W, Zhou ZZ, Xia
YJ, Tu W, Li PY, Feng ZH and Tian DA: Sirtuin 6 promotes
transforming growth factor-β1/H2O2/HOCl-mediated enhancement of
hepatocellular carcinoma cell tumorigenicity by suppressing
cellular senescence. Cancer Sci. 106:559–566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Y, Nie L, Xu K, Fu Y, Zhong J, Gu K
and Zhang L: SIRT6, a novel direct transcriptional target of
FoxO3a, mediates colon cancer therapy. Theranostics. 9:2380–2394.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brucker DP, Maurer GD, Harter PN, Rieger J
and Steinbach JP: FOXO3a orchestrates glioma cell responses to
starvation conditions and promotes hypoxia-induced cell death. Int
J Oncol. 49:2399–2410. 2016. View Article : Google Scholar : PubMed/NCBI
|
